REPL - レプリミュ―ン (Replimune Group Inc.) レプリミュ―ン



symbol REPL
会社名 Replimune Group Inc (レプリミュ―ン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Replimune Group Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP RP2 and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate RP1 in approximately 150 patients with a range of solid tumors.   レプリミュ―ンは米国のバイオ医薬品企業。臨床段階で、がん治療における腫瘍崩壊性免疫療法の開発に従事する。同社は独自の「Immulytic」プラットフォ―ムを使用して、固形腫瘍に対する患者の免疫システムを最大限に活性化させることを目的とする医薬品候補を開発する。本社所在地はマサチュ―セッツ州ウォ―バ―ン。   Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
本社所在地 18 Commerce Way Woburn MA 01801 USA
電話番号 +1 781-995-2443
設立年月日 42917
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 44人
EBITDA EBITDA(百万ドル) -21.81300
終値(lastsale) 12.41
時価総額(marketcap) 391581069.52
時価総額 時価総額(百万ドル) 366.33810
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 400.67010
当期純利益 当期純利益(百万ドル) -26.19400
決算概要 決算概要 BRIEF: For the three months ended 30 June 2018 Replimune Group Inc revenues was not reported. Net loss increased from $3.6M to $10M. Higher net loss reflects Other Non Operating I/E increase from $0K to $5.5M (expense) Research and development increase of 68% to $3.8M (expense) General and administrative increase from $861K to $1.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.12 to -$0.32.


 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 レプリミュ―ン REPL Replimune Group Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)